Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Discovery of and Use of Fragments of DOC1 as Antiangiogenic and Antitumor Therapy

Posted Jun 13 2010 5:00pm

Description of Invention:
This invention describes small cDNA fragments of the coding region for wild type filamin A interacting protein 1-like (FILIP1L), previously known as down-regulated in ovarian cancer 1-like (DOC1) and variant 2 of FILIP1L genes that encode proteins that result in the inhibition of cell migration and motility, induce cell apoptosis and inhibit cell proliferation. These effects can be seen on endothelial cells and on tumor cells. These coding sequences have successfully been delivered to endothelial cells and tumor cells both in vitro and in vivo, and have demonstrated significant anti-tumor activity. In addition, the inventors have for the first time expressed the recombinant protein and developed antibodies to detect the protein fragments by Western, ELISA and immunohistochemistry. The significance of this invention is that it could provide for a series of new anti-cancer therapeutics and for the diagnostic means to follow their expression levels.

Applications:
This invention could provide new anti-cancer therapeutics and diagnostics.

Development Status:
The technology is currently in the pre-clinical stage of development.

Inventors:
Steven K Libutti (NCI)


Relevant Publication:
  1. Mijung Kwon et al. Functional characterization of filamin A interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res. 2008 Sep 15;68(18):7332-7341. [ PubMed abs ]


Licensing Status:
Available for exclusive and non-exclusive license.

Collaborative Research Opportunity:
The National Cancer Institute Hatfield Clinical Research Center is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Discovery of and Use of Fragments of DOC1 as Antiangiogenic and Antitumor Therapy. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Therapeutics
In-vitro Data



For Additional Information Please Contact:
Whitney Hastings
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: hastingw@mail.nih.gov
Phone: 301-451-7337
Fax: 301-402-0220


Ref No: 1850

Updated: 06/2010

Post a comment
Write a comment:

Related Searches